Loading stock data…
$20.07-1.02 (-4.84%)
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs).
Tectonic Therapeutic, Inc. in the Healthcare sector is trading at $20.07 with a market capitalization of $736M. Wall Street consensus targets $71.00 (9 analysts), implying a +253.8% move over the next 12 months. The stock is currently near its 52-week low of $15.52, remaining 28.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$24.22M↑ | -$27.30M↓ | -$21.52M↑ | -$21.89M↑ | -$22.33M |
| Net Income | -$22.29M↑ | -$25.24M↓ | -$19.23M↓ | -$19.04M↑ | -$19.98M |
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the ...